

Claims

1-59. (Cancelled)

60. (Currently amended) A ~~purified~~ FGFR1(IIIc) antibody or Fv (fragment variable) thereof that binds FGFR1(IIIc) comprising a heavy chain variable region (HCVR) and a light chain variable region (LCVR), wherein the HCVR comprises the amino acid sequence of SEQ ID NO: 15 and the LCVR comprises the amino acid sequence of SEQ ID NO: 16.

61-67 (Cancelled)

68. (New) An FGFR1c (IIIc) antibody, or Fv (fragment variable) thereof, comprising a heavy chain variable region (V_H) and a light chain variable region (V_L), wherein the V_H comprises complementarity determining regions (CDRs) V_H CDR1, V_H CDR2, and V_H CDR3 and wherein the V_L comprises CDRs V_L CDR1, V_L CDR2, and V_L CDR3, wherein V_H CDR1 is SEQ ID NO:9, V_H CDR2 is SEQ ID NO: 10, V_H CDR3 is SEQ ID NO: 11, V_L CDR1 is SEQ ID NO: 12, V_L CDR2 is SEQ ID NO: 13, and V_L CDR3 is SEQ ID NO: 14, wherein the antibody or Fv binds to FGFR1(IIIc).

69. (New) The antibody of claim 68 comprising two heavy chain variable regions (V_H) and two light chain variable regions (V_L), wherein each V_H comprises complementarity determining regions (CDRs) V_H CDR1, V_H CDR2, and V_H CDR3 and wherein each V_L comprises CDRs V_L CDR1, V_L CDR2, and V_L CDR3, wherein V_H CDR1 is SEQ ID NO:9, V_H CDR2 is SEQ ID NO: 10, V_H CDR3 is SEQ ID NO: 11, V_L CDR1 is SEQ ID NO: 12, V_L CDR2 is SEQ ID NO: 13, and V_L CDR3 is SEQ ID NO: 14.

70. (New) A pharmaceutical composition comprising the antibody or Fv (fragment variable) thereof of claim 69 and a pharmaceutically acceptable carrier.

71. (New) A method of treating obesity in a mammal comprising administering the antibody or Fv of claim 69 to the mammal, wherein food intake is reduced to treat obesity.

72. (New) A method of reducing food intake in a mammal comprising administering the antibody or Fv of claim 69 to the mammal.